Is AxoGen, Inc. (AXGN) a Buy, Sell, or Hold?
NASDAQ : AXGN
AxoGen, Inc.
$38.72 USD
-$0.05 (-0.13%)
- Volume
- 1.06M
- Average Volume
- 1.28M
- Market Capitalization
- $2.06B
- P/E Ratio
- -61.25
- Dividend Yield
- 0.00%
- Price Target
- $49.00
- Year High
- $46.95
- Year Low
- $11.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.10
| Source | Headline |
|---|---|
|
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. globenewswire.com - 2026-07-15 07:00:00 |
|
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. globenewswire.com - 2026-07-15 07:00:00 |
|
AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance. investors.com - 2026-06-05 14:25:58 |
|
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified. marketbeat.com - 2026-05-14 11:07:07 |
|
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript seekingalpha.com - 2026-05-13 18:00:46 |
|
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla. globenewswire.com - 2026-04-30 07:00:00 |
|
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-04-28 17:41:31 |
|
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago. zacks.com - 2026-04-28 09:16:41 |
|
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla. globenewswire.com - 2026-04-28 07:00:00 |
|
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets. fool.com - 2026-04-26 10:38:05 |
|
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2026-04-21 11:06:49 |
|
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2026-04-17 08:00:56 |
